Vimarsana
Biggest News Aggregation in the World

Salus Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Salus Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Salus Life Sciences Today - Breaking & Trending Today

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors - Vimarsana News

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

– Accomplished industry veteran brings deep strategic and operational expertise ...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call Transcript - Vimarsana News

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2023 Earnings Call Transcript

Operator: Good morning. And welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2023 Earnings Conference Call. Currently, all participants are on a listen-only mode.

TriSalus Life Sciences, Inc. Q4 sales increase - Vimarsana News

TriSalus Life Sciences, Inc. Q4 sales increase

TriSalus Life Sciences, Inc. (TLSI) reported Loss for fourth quarter of -$36.309 million The company's bottom line totaled -$36.309 million, or -$1.56 per share.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting - Vimarsana News

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery...

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors - Vimarsana News

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

DENVER--(BUSINESS WIRE)--Feb 29, 2024--